NEXEL

Nexel Co., Ltd. is a biotechnology company founded in South Korea in 2012 that specialises in the development and manufacture of products based on induced pluripotent stem cells (iPSCs). The company was founded as a spin-off from Korea University and is based in Seoul. Nexel offers iPSC-derived cardiomyocytes, hepatocytes and neurons, which play a key role in drug research and toxicity testing.

Its product portfolio includes Cardiosight-S, a platform for iPSC-derived cardiomyocytes, which is used for applications such as cytotoxicity testing, drug testing, 3D printing and the creation of organoids and spheroids.

The company pursues a vision of improving the quality of life through innovative research and the treatment of previously incurable diseases. It is also developing therapeutic proteins for diseases such as liver fibrosis.

The company's CEO, Choongseong Han, has been instrumental in the company's innovation. Under his leadership, Nexel has expanded its services to include the NeXST Cardiac Safety Service, which improves the accuracy of drug toxicity testing.

The company is also developing new drug candidates, including NP-011, a fibrosis-targeted therapeutic currently in clinical trials.

Search for products by NEXEL

NEXEL products by Product Category

• 
  Cell Lines & Cell Culture
• 
  Reagents & Chemicals
• 
  All Products